Magellan Midstream (MMP) Beats on Q3 Earnings and Sales
Regeneron Pharmaceuticals, Inc. REGN was a big mover last session, as the company saw its shares rise 7% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This continues the recent uptrend for the company—as the stock is now up 12.2% in the past one-month time frame.
The move came after the company reported solid second-quarter 2018 results.
The company has seen three positive estimate revisions in the past few weeks, while its Zacks Consensus Estimate for the current quarter has also moved higher over the past few weeks, suggesting that more solid trading could be ahead for Regeneron Pharmaceuticals. So make sure to keep an eye on this stock going forward to see if this recent jump can turn into more strength down the road.
Regeneron Pharmaceuticals currently has a Zacks Rank #2 (Buy) while its Earnings ESP is negative.
Regeneron Pharmaceuticals, Inc. Price
Regeneron Pharmaceuticals, Inc. Price | Regeneron Pharmaceuticals, Inc. Quote
Investors interested in the Medical - Biomedical and Genetics industry may consider Celgene Corporation CELG, which has a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Is REGN going up? Or down? Predict to see what others think:Up or Down
Will You Make a Fortune on the Shift to Electric Cars?
Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge.
With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research.
It's not the one you think.
See This Ticker Free >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Regeneron Pharmaceuticals, Inc. (REGN) : Free Stock Analysis Report
Celgene Corporation (CELG) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research